# Safety and Efficacy of LMWH Versus Rivaroxaban in Chinese Patients Hospitalized With Acute Coronary Syndrome

Study · id `cardio:ct-nct03363035` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT03363035](<https://clinicaltrials.gov/study/NCT03363035>), retrieved 26 October 2026. No person wrote or checked this page.

Also called: NCT03363035

Browse, organ or system: Heart  
Browse, condition area: Coronary and vascular disease; Acute care and long-term living  

## In plain language

A phase 4 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 2055 participants.

## Technical summary

Registry record NCT03363035. Randomized; no masking; primary purpose treatment. Start 2018-01-15 (actual); primary completion 2021-11-11 (actual). Results not posted.

## Key facts

- Design: Interventional study; randomized; no masking; primary purpose treatment
- Phase: Phase 4
- Enrolled: 2055 participants (enrolled count; ClinicalTrials.gov record NCT03363035, source copy `cardio:ctgov-nct03363035-2022-02-22`, retrieved 2026-10-26)
- Started: 2018-01-15 (actual) (ClinicalTrials.gov record NCT03363035, source copy `cardio:ctgov-nct03363035-2022-02-22`, retrieved 2026-10-26)
- Primary completion: 2021-11-11 (actual) (ClinicalTrials.gov record NCT03363035, source copy `cardio:ctgov-nct03363035-2022-02-22`, retrieved 2026-10-26)
- Completion: 2021-11-30 (actual) (ClinicalTrials.gov record NCT03363035, source copy `cardio:ctgov-nct03363035-2022-02-22`, retrieved 2026-10-26)
- Countries: China (ClinicalTrials.gov record NCT03363035, source copy `cardio:ctgov-nct03363035-2022-02-22`, retrieved 2026-10-26)
- Care setting: Not reported
- Registry status: "COMPLETED" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct03363035-2022-02-22`, retrieved 2026-10-26)

## The registry's words

- Brief title: Safety and Efficacy of LMWH Versus Rivaroxaban in Chinese Patients Hospitalized With Acute Coronary Syndrome
- Acronym: H-REPLACE
- Condition: Acute Coronary Syndrome
- Condition: Myocardial Infarction
- Condition: Myocardial Ischemia
- Condition: Unstable Angina
- Intervention (Drug): Rivaroxaban 2.5 mg
- Intervention (Drug): Rivaroxaban 5 mg
- Intervention (Drug): Enoxaparin
- Lead sponsor: Second Xiangya Hospital of Central South University
- Lead sponsor class: OTHER

## Connected pages

- Registry condition terms include this condition: Acute coronary syndrome (`cardio:acute-coronary-syndrome`)
- Registry condition terms include this condition: Heart attack (myocardial infarction) (`cardio:myocardial-infarction`)
- Registry condition terms include this condition: Unstable angina (`cardio:unstable-angina`)
- Registry intervention name matches this record: Enoxaparin (`core:enoxaparin`)
- Registry lists this organization as the lead sponsor: Second Xiangya Hospital of Central South University (`cardio:org-second-xiangya-hospital-of-central-south-university`)

### Other papers using this trial's data

- Registry lists this paper as a derived reference; the paper's PubMed record names this trial's registry number and no other, PubMed types it as a trial report dated on or after the primary completion, neither its types nor its title mark it as a protocol, a design, an observational study or work outside the trial's own data, and PubMed shows no retraction or expression of concern: Effect of Rivaroxaban vs Enoxaparin on Major Cardiac Adverse Events and Bleeding Risk in the Acute Phase of Acute Coronary Syndrome: The H-REPLACE Randomized Equivalence and Noninferiority Trial (`cardio:pubmed-36763358`)
- Registry lists this paper as a derived reference; the paper's PubMed record names this trial's registry number and no other, PubMed types it as a trial report dated on or after the primary completion, neither its types nor its title mark it as a protocol, a design, an observational study or work outside the trial's own data, and PubMed shows no retraction or expression of concern: U-shaped association between plasma cyclic guanosine monophosphate-adenosine monophosphate (cGAMP) levels and myocardial infarction (`cardio:pubmed-39972291`)

Courtesy of the U.S. National Library of Medicine.

## Provenance

Content hash: 0a9930b48fc265f219d265cf607a475600b258a6df5cd1f603fd29042c130539
Last substantive edit: 2026-11-08
Evidence last checked: Not recorded
